RiNA and 5 Prime Take Over Roche’s RTS Protein-Expression Portfolio
Roche’s focus on genomics led to decision to pass this technology on to specialists.!--h2>
Roche has transferred its entire portfolio of Roche Applied Science RTS cell-free protein-expression kits to German companies RiNA and 5 Prime. RiNA will manufacture the products, and 5 Prime will be responsible for sales, support, and distribution of the RTS portfolio worldwide.
Roche says that because of its own focus on new genomics technologies, the RTS technology is better placed with a company that is more specialized in proteomics. RiNA has been working with Roche for a number of years and was involved in the development of the RTS technology from the start.
RiNA CEO, Leo W. Tristram, says that the RTS kits ideally complement its own product portfolio and services for cell-free biosynthesis. “Together with 5 Prime products for purifying and detecting recombinant proteins, RTS technology will form a strong basis for joint development of innovative products in this dynamic field.”